Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Court Finds Data Manipulation, but Not False Advertising: Diovan Case
A former employee of Novartis Pharma tampered with data involving the company’s major hypertension drug Diovan (valsartan), but the publication of scientific papers based on the manipulated data does not constitute false or misleading advertising banned under the law, according…
To read the full story
Related Article
- Japan Top Court Rejects Prosecutors’ Appeal in Diovan Case; Novartis Not Guilty
June 30, 2021
- High Court Upholds Not-Guilty Ruling for Novartis, Ex-Employee in Diovan Case
November 20, 2018
- Tokyo Prosecutors File Appeal in Diovan Case
March 30, 2017
- Novartis Vows Continued Reforms despite Not-Guilty Diovan Ruling
March 17, 2017
- Recovering Trust in Clinical Research Is Urgent Task: Shiozaki
March 17, 2017
- Novartis, Ex-Employee Found Not Guilty in Diovan Case
March 16, 2017
- Diovan Data Manipulation Case Closed, Ruling Due Out in March
December 16, 2016
- Prosecutors Seek 2.5 Years in Jail for Ex-Novartis Employee: Diovan Case
November 28, 2016
- Ex-Novartis Employee Pleads Not Guilty over Diovan Data Manipulation
December 17, 2015
- Ex-Novartis Employee, Japan Unit Indicted over Diovan Data Manipulation
July 1, 2014
- Ex-Novartis Employee Suspected of Manipulating the Number of Events in Sub-Analysis
June 13, 2014
BUSINESS
- Sanofi Delays Japan Launch of Efluelda by One Year, Defers NIP Rollout
July 22, 2026
- Towa Pins NO2 as Key Driver of Nitrosation, Eyes Lower Filter Costs
July 22, 2026
- FRONTEO Taps Bayer Ex-Chair Eiki as Advisor
July 22, 2026
- JCR Grabs 1st Overseas Nod for Izcargo in UAE
July 22, 2026
- Carna Bio’s AML Drug Candidate Earns US Orphan Tag
July 22, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…